Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement
July 24 (Reuters) -Thermo Fisher TMO.N on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.
Contract drug manufacturers witnessed cut back on spending by their biotech clients in 2023 amid rising interest rates.
The public funding environment for early-stage biotechs is expected to improve in the second half of this year, on hopes ofinterest rate cuts from the Federal Reserves in September. Some analysts have noted that funding for biotechs could stabilize due to a strong 2023 for regulatory approvals in the United States.
The forecast raise from Thermo comes a day after rival DanaherDHR.N said that it witnessed "positive momentum" for its products and services used to develop biological drugs. Yet, it reaffirmed that core revenue is expected to be down low-single digits this year.
Thermo Fisher now expects annual profit in a range of $21.29 to $22.07 per share, compared with previous forecast of $21.14 to $22.02 per share.
Yet, shares of the medical equipment maker fell 3% to $535 in premarket trading as the raised forecast came in below analysts' expectations of $21.70 per share for the year, according to LSEG data.
On an adjusted basis, the Waltham, Massachusetts-based company earned $5.37 per share for the quarter ended June 29, compared with analysts' expectations of $5.12 per share.
Sales in its laboratory and biopharma services segment, which provides products used in clinical trials, came in at $5.76 billion, above analysts' expectations of $5.48 billion.
Revenue from that segment makes up more than half of Thermo Fisher's total sales, which were $10.54 billion for the quarter, slightly beating estimates of $10.51 billion.
Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
